Method for detecting replication or colonization of a biological therapeutic

• US 8,859,256 B2
• Filed: 10/05/2012
• Issued: 10/14/2014
• Est. Priority Date: 10/05/2011
• Status: Active Grant

• Current Assignee: Genelux Corporation
• Original Assignee: Genelux Corporation
• Inventors: Szalay, Aladar A., Stritzker, Jochen, Hess, Michael
• Primary Examiner(s): Carlson, Karen Cochrane
• Application Number:
  US13/573,845
• Publication Number:
  US 20130130292A1
• Time in Patent Office: 739 Days
• Field of Search: 435/210, 435/320.1
• US Class Current: 435/210
• CPC Class Codes: C12Q 1/6897 involving reporter genes operably linked to promoters
• CPC Class Codes: G01N 21/6428 Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" in vivo A61B5/00; immunoassay G01N33/53
• CPC Class Codes: G01N 2800/52 Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
• CPC Class Codes: G01N 33/56911 Bacteria
• CPC Class Codes: G01N 33/56983 Viruses
• CPC Class Codes: G01N 33/573 for enzymes or isoenzymes

Abstract

Methods for detecting replication in or colonization of a host by a biological therapeutic, such as an oncolytic virus, cells administered for cell therapy and gene therapy vectors, are provided. In the methods, a product produced by the biological therapeutic is detected in a sample of tissue or body fluid distinct from the administered therapy or locus thereof, thereby permitting assessment of the therapy and/or monitoring its progress.

Claims

1. A method for treating cancer and monitoring therapeutic progress in a subject having tumors, said method comprising:

a) administering to said subject an oncolytic virus encoding a β

-glucuronidase, wherein said oncolytic virus targets and treats cancer and the β

-glucuronidase activity indicates oncolytic viral colonization or replication in said cancer;

b) obtaining a sample from a subject, wherein said sample is a body fluid or tissue sample that is not a tumor sample;

c) detecting β

-glucuronidase activity in the sample, wherein said detection is by the addition of a substrate for β

-glucuronidase; and

d) determining the presence of a product catalyzed by the reaction of the β

-glucuronidase with the substrate,

wherein the detection of the product indicates that the oncolytic virus has colonized or is replicating in a tumor tissue or cell in the subject and is treating said tumor tissue or cell and oncolytic viral therapy be continued.

2. The method of claim 1, wherein the oncolytic virus is selected from among an poxvirus, adenovirus, reovirus, herpes virus, adeno- associated virus, lentivirus, retrovirus, rhabdovirus, papillomavirus, vesicular stomatitis virus, measles virus, Newcastle disease virus, picornavirus, sindbis virus, parvovirus, coxsackievirus, influenza virus, mumps virus, poliovirus and semliki forest virus.

3. The method of claim 2 wherein the virus is a poxvirus that is selected from among an orthopoxvirus, parapoxvirus, avipoxvirus, capripoxvirus, leporipoxvirus, suipoxvirus, molluscipoxvirus, yatapoxvirus, entomopoxvirus A, entomopoxvirus B, and entomopoxvirus C.

4. The method of claim 2, wherein the virus is a poxvirus.

5. The method of claim 4, wherein the poxvirus is a vaccinia virus.

6. The method of claim 5, wherein the vaccinia virus is a Lister strain virus.

7. The method of claim 5, wherein the vaccinia virus is an LIVP virus or clonal variant of an LIVP virus.

8. The method of claim 7, wherein the virus is the variant of the LIVP virus that is the virus designated GLV-Ih68.

9. The method of claim 1, wherein the β

-glucuronidase is a human or bacterial β

-glucuronidase.

10. The method of claim 9, wherein the β

-glucuronidase comprises the amino acid sequence set forth in SEQ ID NO;

121, or a catalytically active portion thereof, or the amino acid sequence having at least 85% sequence identity to the amino acid sequence set forth in SEQ ID NO;

121.

11. The method of claim 9, wherein the β

-glucuronidase comprises the amino acid sequence set forth in SEQ ID NO;

4, or a catalytically active portion thereof, or the amino acid sequence having at least 85% sequence identity to the amino acid sequence set forth in SEQ ID NO;

4.

12. The method of claim 9, wherein the β

-glucuronidase comprises the amino acid sequence set forth in any of SEQ ID NOS;

4, 114-121, 128, 130, 132, 134, 136, 138, 140, 142, 144 and 146, or a catalytically active portion thereof, or the amino acid sequence having at least 85% sequence identity to the amino acid sequence set forth in any of SEQ ID NOS;

4, 114-121, 128, 130, 132, 134, 136, 138, 140, 142, 144 and 146.

13. The method of claim 1, wherein the substrate from the group consisting of fluorescein di-β

-D-glucuronide (FDGlcU), 4-methylumbelliferyl-β

-D-glucuronide (4-MUG), carboxyumbellifery1 β

-D-glucuronide (CUGlcU), 5-(pentafluorobenzoylamino)-fluorescein di-β

-D-glucuronide (PFB-FDGlcU), C12-fluorescein β

-D-Glucuronidase, 5-bromo-4-chloro-3-indoly1 β

-D-glucuronide (X-GlcU or BCIG), p-nitrophenyl- β

-D-glucuronide, red-β

-D-GlcU,CHA (magenta-b-D-GlcA;

5-bromo-6-chloro-3-indolyl-b-D-glucuronide, cyclohexylammonium salt), rose-β

-D -GlcU,CHA (salmon-β

-D-GlcUA;

5-bromo-6-chloro-3-indolyl-β

-D -glucuronide, cyclohexylammonium salt), phenyl-β

-D-glucuronide, and pharmaceutically acceptable salts thereof.

14. The method of claim 13, wherein the substrate is selected from among fluorescein di-β

-D-glucuronide (FDGIcU) and 4-methylumbelliferyl-β

-D-glucuronide (4-MUG).

15. The method of claim 1, wherein the sample is a body fluid that is selected from among blood, plasma, serum, lymph, ascetic fluid, cystic fluid, urine, nipple exudates, sweat, tears, saliva, mouth gargle, peritoneal fluid, cerebrospinal fluid (CSF), synovial fluid, aqueous humour, vitreous humour, amniotic fluid, bile, cerumen (earwax), Cowper'"'"'s fluid (pre-ejaculatory fluid), Chyle, Chyme, female ejaculate, interstitial fluid, lymph fluid, menses, breast milk, mucus, snot, phlegm, pleural fluid, pus, sebum, semen, vaginal lubrication, and feces.

16. The method of claim 15, wherein the sample is collected between or between about 12 hours to 1 month after treatment with the oncolytic virus.

17. The method of claim 15, wherein the sample is obtained within 1 week of treatment with the virus, and detection of the β

-glucuronidase activity in the sample indicates that the virus is replicating in tumor cells and is effective for treatment.

18. The method of claim 15, wherein the sample is obtained periodically following administration of the virus to monitor the progress of treatment by detecting an increase in amount of β

-glucuronidase in the sample, indicating replication of the virus in tumors, followed by a decrease indicating that tumors are shrinking.

19. The method of claim 1, wherein the cancer comprises a bladder tumor, breast tumor, prostate tumor, glioma tumor, adenocarcinoma, ovarian carcinoma, and pancreatic carcinoma, liver tumor, skin tumor, pancreatic cancer, non-small cell lung cancer, multiple myeloma, leukemia, lung and bronchus tumor, breast tumor, colon and rectum tumor, kidney tumor, stomach tumor, esophagus tumor, liver and intrahepatic bile duct tumor, urinary bladder tumor, brain tumor and other nervous system tumor, head and neck tumor, oral cavity tumor and pharynx tumor, cervix tumor, uterine corpus tumor, thyroid tumor, ovary tumor, testes tumor, prostate tumor, malignant melanoma, cholangiocarcinoma, thymoma, non-melanoma skin cancer;

hematologic tumor, malignancy, childhood leukemia and lymphoma, multiple myeloma, Hodgkin'"'"'s disease, lymphomas of lymphocytic and cutaneous origin, acute and chronic leukemia, acute lymphoblastic leukemia, acute myelocytic leukemia, chronic myelocytic leukemia, plasma cell neoplasm or lymphoid neoplasm or is a cancer associated with HIV infection.

20. The method of claim 1, wherein the cancer is a solid tumor.